Socioeconomic Factors Associated with Lack of Treatment in Early Stage Non-Small Cell Lung Cancer.

Socioeconomic Factors Associated with Lack of Treatment in Early Stage Non-Small Cell Lung Cancer. Cancer Invest. 2019 Sep 18;:1-6 Authors: Dalwadi SM, Zhang J, Bernicker EH, Butler EB, Teh BS, Farach AM Abstract With modern radiotherapy, stage I non-small cell lung cancer (S1NSCLC) cure is extended to nonsurgical candidates. Despite this, some S1NSCLC remains untreated. We aim to identify factors associated with no treatment. 62,213 S1NSCLC cases were identified (SEER: 2004-2012). Demographics were compared using Chi-squared. Multivariate analysis was performed using COX proportional HR. 11.9% of the 7373 patients lacked treatment. No insurance, Medicaid-dependence, unmarried status, advancing age, lower income, African American and Asian/Pacific Islander race, and male sex are associated with no treatment (p 
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research

Related Links:

ABSTRACT Objective: Preoperative functional evaluation is central to optimizing the identification of patients with non-small cell lung cancer (NSCLC) who are candidates for surgery. The minute ventilation/carbon dioxide output (VE/VCO2) slope has proven to be a predictor of surgical complications and mortality. Pulmonary rehabilitation programs (PRPs) could influence short-term outcomes in patients with COPD undergoing lung resection. Our objective was to evaluate the effects of a PRP on the VE/VCO2 slope in a cohort of patients with COPD undergoing lung resection for NSCLC. Methods: We retrospectively evaluated 25 consec...
Source: Jornal Brasileiro de Pneumologia - Category: Respiratory Medicine Source Type: research
One-third of patients with locally advanced non-small cell lung cancer treated with durvalumab developed symptomatic pneumonitis.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Conclusion: This study identified a local “driver-network” and its upstream regulators responsible for the cell proliferation in NSCLC, which could be promising biomarkers and therapeutic targets for NSCLC treatment.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We describe here a case of 48 y.o. male patient with ALK-positive NSCLC who was clinically managed for 6.5 years from the diagnosis. The tumor was surgically resected, but 8 months later multiple brain metastases were discovered. The patient started receiving platinum-based chemotherapy and then was enrolled in a clinical trial of second-generation ALK inhibitor ceritinib, which resulted in a 21 months stabilization. Following disease relapse, the patient was successfully managed for 33 months with different lines of chemo- and local ablative therapies. Chemotherapy regimens, including off-label combination of crizotinib +...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, tumor imaging phenotypes that are driven by somatic mutations may be predicted by radiomics based on PET/CT images.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, miR-107 showed low expression in NSCLC serum samples, and it could suppress cell proliferation, migration and arrest cell cycle in NSCLC cell lines. Results revealed that miR-107 could inhibit the expression of transforming growth factor β receptor 2 (TGFβR2) via targeting TGFβR2. Downregulation of TGFβR2 also suppressed cell proliferation, migration and cell cycle in NSCLC cell lines. Our data suggested that miR-107 could inhibit the progression of NSCLC by targeting TGFβR2.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. The inhibition of epidermal growth factor receptor (EGFR) signaling by tyrosine kinase inhibitors or monoclonal antibo...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
With the popularization of Next-generation sequencing technology, targeted cancer therapy based on gene mutations has attracted more and more attention. Aberrant activated mitogen-activated protein kinases (MAPK) pathway is considered to play a crucial role in the occurrence and development of various cancers [1]. Various mutations in pathway components including MEK1/2 can cause the aberrant activation of MAPK signaling pathway [2]. As oncogenic mutations, MEK1 mutations were widely observed in many cancers [1,3,4], while trametinib, a MEK1/2 inhibitor, was limited to treat BRAF-mutant melanoma and non-small-cell lung can...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research
Anaplastic lymphoma kinase fusion gene-positive (ALK+) disease occurs in around 5% of patients with advanced non-small-cell lung cancer (NSCLC) [1]. Alectinib, a potent ALK inhibitor, received full approval from the US Food and Drug Administration on November 6, 2017 for the treatment of patients with advanced ALK+ NSCLC [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
We read with great interest the study by Solassol et al [1]. They reported a successful case of using sequential treatment with dabrafetinib/trametinib and osimertinib in a patient with EGFR exon 19 deletion mutation non-small cell lung cancer [NSCLC] with an acquired BRAFV600E mutation. Notably, in their case, dabrafetinib/trametinib and osimertinib were not administrated concurrently. Here, we reported a patient with EGFR L858R/T790  M NSCLC harboring an acquired BRAFV600E mutation rapidly responded to the concurrently combination of dabrafenib, trametinib and osimertinib after treatment with osimertinib.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Insurance | Lung Cancer | Medicaid | Non-Small Cell Lung Cancer | Uninsured